Systematic reanalysis of genomic data by diagnostic laboratories: a scoping review of ethical, economic, legal and (psycho)social implications.
Marije A van der Geest et al. Eur J Hum Genet 2024 3 (Posted Mar 18, 2024 9AM)
Improving Noninvasive Colorectal Cancer Screening.
John M Carethers et al. N Engl J Med 2024 3 (11) 1045-1046 (Posted Mar 14, 2024 10AM)
Cost-Effectiveness of Population-Based Multigene Testing for Breast and Ovarian Cancer Prevention.
Fangjian Guo et al. JAMA Netw Open 2024 2 (2) e2356078 (Posted Feb 15, 2024 9AM)
Cost-Effectiveness of Gene-Specific Prevention Strategies for Ovarian and Breast Cancer.
Xia Wei et al. JAMA Netw Open 2024 2 (2) e2355324 (Posted Feb 11, 2024 10AM)
Singh Sid, et al. British journal of community nursing 2024 0 0. (5) 224-230
An evaluation of the cost-effectiveness of population genetic screening for familial hypercholesterolemia in US patients.
Lauren E Hendy et al. Atherosclerosis 2024 393117541
Cost-effectiveness of BRCA1 testing at time of obstetrical prenatal carrier screening for cancer prevention.
Shayan M Dioun et al. Am J Obstet Gynecol 2024
Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer.
Tarun Mehra et al. PLoS One 2024 19(4) e0301271
Is Risk-Stratifying Patients with Colorectal Cancer Using a Deep Learning-Based Prognostic Biomarker Cost-Effective?
Anna Kenseth et al. Pharmacoeconomics 2024
Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening With a Blood Test That Meets the Centers for Medicare & Medicaid Services Coverage Decision.
Rosita van den Puttelaar et al. Gastroenterology 2024
A Review of the Cost-Effectiveness Evidence for FDA-Approved Cell and Gene Therapies.
Sumaya Abuloha et al. Hum Gene Ther 2024
Economic evaluation of germline genetic testing for breast cancer in low- and middle-income countries: a systematic review.
Sook Pin Goh et al. BMC Cancer 2024 24(1) 316
The cost-effectiveness of germline BRCA testing-guided olaparib treatment in metastatic castration resistant prostate cancer.
Srinivas Teppala et al. Int J Technol Assess Health Care 2024 40(1) e14
Familial hypercholesterolemia in children and the importance of early treatment.
Sibbeliene E van den Bosch et al. Curr Opin Lipidol 2024
Assisting the implementation of screening for type 1 diabetes by using artificial intelligence on publicly available data.
Pedro F Teixeira et al. Diabetologia 2024
A UK prospective multicentre decision impact, decision conflict and economic evaluation of the 21-gene assay in women with node+ve, hormone receptor+ve, HER2-ve breast cancer.
Simon Holt et al. Br J Cancer 2024
Assessing the utility of measurement methods applied in economic evaluations of pharmacogenomics applications.
Vasileios Fragoulakis et al. Pharmacogenomics 2024
Measuring Costs of Cardiovascular Disease Prevention for Patients with Familial Hypercholesterolemia in Administrative Claims Data.
Lauren E Passero et al. High Blood Press Cardiovasc Prev 2024
Estimating Hidden Population Size of COVID-19 Using Respondent- Driven Sampling Method - A Systematic Review.
Alinaghi Seyed Ahmad Seyed, et al. Infectious disorders drug targets 2024 0 0.
Gene Therapy Versus Common Care for Eligible Individuals With Sickle Cell Disease in the United States : A Cost-Effectiveness Analysis.
Anirban Basu et al. Ann Intern Med 2024
Health Economic Evaluations of Hemochromatosis Screening and Treatment: A Systematic Review.
Malvina Hoxha et al. Pharmacoecon Open 2024
Next-generation sequencing in pharmacogenomics - fit for clinical decision support?
Yitian Zhou et al. Expert Rev Clin Pharmacol 2024
A cost-effectiveness analysis of an integrated clinical-radiogenomic screening program for the identification of BRCA 1/2 carriers (e-PROBE study).
A Di Pilla et al. Sci Rep 2024 14(1) 928
Combined population genomic screening for three high-risk conditions in Australia: a modelling study.
Paul Lacaze et al. EClinicalMedicine 2024 66102297
Exploring the Cost Effectiveness of a Whole-Genome Sequencing-Based Biomarker for Treatment Selection in Patients with Advanced Lung Cancer Ineligible for Targeted Therapy.
Zakile A Mfumbilwa et al. Pharmacoeconomics 2024
Implementing HLA-B*58:01 testing prior to allopurinol initiation in Malaysian primary care setting: A qualitative study from doctors' and patients' perspective.
Wei Leik Ng et al. PLoS One 2024 19(1) e0296498
Real-world diagnostic outcomes and cost-effectiveness of genome-wide sequencing for developmental and seizure disorders: evidence from Canada.
Dean A Regier et al. Genet Med 2024 101069
Identification of oral therapeutics using an AI platform against the virus responsible for COVID-19, SARS-CoV-2.
Bess Adam, et al. Frontiers in pharmacology 2024 0 0. 1297924
Sotorasib versus Docetaxel for treatment of US and Chinese patients with advanced non-small-cell lung cancer with KRAS p.G12C-mutated: A cost-effectiveness analysis to inform drug pricing.
Yunlin Jiang et al. Medicine (Baltimore) 2023 102(50) e36387
Cost-Effectiveness of Comprehensive Genomic Profiling in Patients With Non-Small Cell Lung Cancer for the Colombian Health System.
Oscar Gamboa et al. Value Health Reg Issues 2023 39115-125
Applications of digital Medicine in oncology: Prospects and challenges.
Hewei Ge et al. Cancer Innov 2023 1(4) 285-292
Feasibility of artificial intelligence its current status, clinical applications, and future direction in cardiovascular disease.
Bhushan Sandeep et al. Curr Probl Cardiol 2023 49(2) 102349
Opportunistic Screening for Asymptomatic Left Ventricular Dysfunction Using Electrocardiographic Artificial Intelligence: A Cost-Effective Approach.
Wei-Ting Liu et al. Can J Cardiol 2023
A systematic review of cost-effectiveness analysis of different screening strategies for familial hypercholesterolemia.
Rui Meng et al. J Clin Lipidol 2023
More
About Economic Evaluation PHGKB
Economic Evaluation PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other materials that identify, measure, value, and compare the costs and consequences of genomic and other precision health interventions, policies and programs. Economic Evaluation PHGKB is a specialized database of the overall PHGKB.
Content Summary
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by Public Health Genomics Branch to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Page last updated:May 03, 2024
- Content source: